West Pharmaceutical Services (WST): Price-to-Projected Revenue Ratio

Public company logo of West Pharma (WST)

The forward P/S multiple visualizes the link between the valuation of West Pharmaceutical Services (WST) and its high-tech manufacturing plants in Europe and the US. Price action relies on the production volumes of injectables within the biotech sector. 7.50 serves as the current parameter value, highlighting the company's dominance in the drug delivery systems niche, where stringent component certification makes switching suppliers virtually impossible.

West Pharmaceutical Services, Inc. - WST Market Cap to Future Revenue Ratio (period 07/04/2022 - 11/16/2026)

Analytical breakdowns for westpharma.com (WST)

- stock price and consensus target price:
Comprehensive company analysis:West Pharma Corp (WST)
Manufactured products of West Pharmaceutical Services

The market evaluates West Pharmaceutical Services (WST) through the lens of its hybrid production model's efficiency, where component outsourcing is combined with internal patent control. The forward P/S ratio compares current market capitalization with expected revenue, revealing whether the asset is overbought or if its potential is undervalued. Analysis of this chart allows for the identification of the investment risk point: an excessive increase in the ratio amid stagnating revenues signals an impending price correction.

Competitors of West Pharmaceutical Services (WST)

Price-to-Projected Revenue Ratio Intuitive Surgical Inc ISRG|Forward P/S Multiple Danaher Corporation Inc. DHR|BDX - Price-to-Projected Revenue Ratio|STERIS plc (STE) - Forward Price-to-Revenue Multiple|BAX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Masimo|STVN (stevanatogroup.com) - Forward P/S Multiple|Market Cap to Projected Revenue TFX (Teleflex Incorporated)|Price-to-Projected Revenue Ratio Merit Medical (MMSI)|Envista - Market Cap to Projected Revenue|ICU Medical, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio XRAY (Dentsply Sirona Inc)|LMAT - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio AtriCure Corp ATRC|staar.com (STAA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple ChromaDex Corporation|ZIMV (ZimVie Inc) - Forward P/S Multiple|Market Cap to Projected Revenue ANGO (AngioDynamics)|Price-to-Projected Revenue Ratio Cerus Corp (CERS)|TKNO: Future Price to Revenue|Price-to-Projected Revenue Ratio Monogram Technologies Inc. MGRM|Forward Price to Sales STSS|INFU - Price-to-Projected Revenue Ratio|Forward Price to Sales UTMD (Utah Medical Products Inc.)|KORU Medical Systems Inc. (KRMD) - Price-to-Projected Revenue Ratio|Nyxoah S.A. - Forward Price to Sales|Price-to-Projected Revenue Ratio Microbot Medical, Inc.|Market Cap to Projected Revenue PDEX (Pro-Dex)|Price-to-Projected Revenue Ratio Zentek (ZTEK)|Market Cap to Expected Sales Ratio Elutia Inc|Forward P/S Multiple MLSS (milestonescientific.com)|NXGL: Market Cap to Projected Revenue|Retractable Tech - Forward P/S Multiple|Market Cap to Expected Sales Ratio Harvard Bioscience Inc. HBIO|FEMY: Forward P/S Multiple|MeihuaMed - Forward Price to Sales|Price-to-Projected Revenue Ratio Predictive Oncology Inc|callanjmb.com (CJMB) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Atrion Corporation (ATRI)|Market Cap to Expected Sales Ratio neurometrix.com